William,
I appreciate your concerns and will give you my take on the situation. With the relatively recent purchase of Boston based Oncologics, the Company has clearly defined their go-forward strategy and position in the war against cancer. Although there was already considerable in-house cancer-based knowledge, the guys from Oncologics significantly strengthened the team. Obviously, this part of the Company and the ANA product are in their infancy.
Prior to this acquisition the Company had focused on two primary, promising products -- Colopath & Fibrostat. These products are obviously at later stages in their development, but the Company still has dedicated, qualified resources devoted to them and continues to advance the science. Naturally, at some point an alliance with a major will be considered to take the products to the market and world. As for current discussions, I think that the prospectus refers to initial contact, although I don't know anymore than that, I would not assume that partners have been "lined" up.
Personally, I believe in the core team and am delighted that they have been able to surround themselves with quality people. In the short-term, the price will be a function of a finicky market, but I will be around for the long-term as I like the concepts, the people and the products.
Have a good weekend,
Tim |
